Press release
Non-alcoholic Steatohepatitis (NASH) treatment market is expected to reach $90.97 billion by 2034, with a CAGR of 28.0%
Non-alcoholic Steatohepatitis Treatment Market
๐๐๐ฉ๐จ๐ซ๐ญ ๐๐๐จ๐ฉ๐:
This comprehensive study provides an accurate overview of the worldwide non-alcoholic steatohepatitis treatment market. Comprehensive analyses of sales volume, price, revenue, market share, and important companies are included. The market is further divided into segments by drug, disease stage, distribution channel, and region in the study, which offers a comprehensive picture of the state of the market.
๐๐๐ญ ๐๐ฑ๐๐ฅ๐ฎ๐ฌ๐ข๐ฏ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐ฌ ๐จ๐ ๐๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ:
https://www.polarismarketresearch.com/industry-analysis/non-alcoholic-steatohepatitis-treatment-market/request-for-sample
๐๐๐ซ๐ค๐๐ญ ๐๐๐๐ข๐ง๐ข๐ญ๐ข๐จ๐ง:
Non-alcoholic steatohepatitis treatment (NASH) emphasizes controlling liver inflammation and avoiding additional liver harm. It entails lifestyle modifications, such as losing weight, engaging in regular physical activity, and maintaining a nutritious diet to reduce fat buildup in the liver. Medications might be recommended to manage associated conditions such as diabetes or elevated cholesterol. In critical situations, liver transplantation may be an option. Timely intervention aids in reducing disease progression and enhancing liver performance.
๐๐ซ๐ข๐ฏ๐๐ซ๐ฌ ๐๐ง๐ ๐๐ซ๐๐ง๐๐ฌ:
โ The growing older population globally leads to a higher occurrence of NASH-related liver disease, with elderly individuals more susceptible to conditions like diabetes and hypertension associated with NASH. The surging aging population is expected to drive the market forward during the forecast period.
โ Insulin resistance, prevalent in diabetes, results in fat buildup in the liver, which initiates liver inflammation and fibrosis linked to NASH. The increasing prevalence of type 2 diabetes is majorly contributing to the market development.
๐๐จ๐ฉ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ:
Because there are so many companies in the market, it is expected to be both competitive and fragmented. Here are the top companies in the non-alcoholic steatohepatitis treatment market:
โข Intercept Pharmaceuticals, Inc.
โข Galmed Pharmaceuticals Ltd
โข Inventiva
โข AbbVie Inc.
โข Galectin Therapeutics Inc.
โข Madrigal Pharmaceuticals Inc (Madrigal)
โข NGM Biopharmaceuticals, Inc.
โข Novo Nordisk A/S
โข The Bristol-Myers Squibb Company
โข Gilead Sciences, Inc.
๐๐ฎ๐ฒ ๐๐จ๐ฐ ๐๐ก๐ข๐ฌ ๐๐ซ๐๐ฆ๐ข๐ฎ๐ฆ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ:
https://www.polarismarketresearch.com/buy/4249/0
๐๐๐ ๐ฆ๐๐ง๐ญ๐๐ฅ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค:
๐๐ฒ ๐๐ซ๐ฎ๐ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค (๐๐๐ฏ๐๐ง๐ฎ๐, ๐๐๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง; ๐๐๐๐-๐๐๐๐)
โข Vitamin E and Pioglitazone
โข Obeticholic Acid (OCA)
โข Lanifibranor
โข Semaglutide
โข Resmetirom
โข Aramchol
โข Cenicriviroc
โข Other Drugs
๐๐ฒ ๐๐ข๐ฌ๐๐๐ฌ๐ ๐๐ญ๐๐ ๐ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค (๐๐๐ฏ๐๐ง๐ฎ๐, ๐๐๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง; ๐๐๐๐-๐๐๐๐)
โข NASH Stage F0
โข NASH Stage F1
โข NASH Stage F2
โข NASH Stage F3
โข NASH Stage F4
๐๐ฒ ๐๐ข๐ฌ๐ญ๐ซ๐ข๐๐ฎ๐ญ๐ข๐จ๐ง ๐๐ก๐๐ง๐ง๐๐ฅ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค (๐๐๐ฏ๐๐ง๐ฎ๐, ๐๐๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง; ๐๐๐๐-๐๐๐๐)
โข Hospital Pharmacies
โข Retail and Specialty Pharmacies
โข Other Pharmacies
๐๐จ๐ฎ๐ง๐ญ๐ซ๐ฒ-๐๐ข๐ฌ๐ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ:
According to regional analysis, North America held the largest market share in 2024 because of the significant occurrence of risk factors like obesity, type 2 diabetes, and metabolic syndrome, which play key roles in the increase of NASH cases.
Also, during the projection period, Asia Pacific is anticipated to witness the highest CAGR. The growing recognition of NASH and its associated complications, along with advancements in healthcare infrastructure and broader access to advanced treatment options, is driving the swift expansion of the market in the region.
o North America (U.S., Canada)
o Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
o Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
o Latin America (Brazil, Mexico, Argentina)
o Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)
๐๐จ๐ซ๐ ๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ญ๐๐ฌ๐ญ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ ๐๐ฒ ๐๐จ๐ฅ๐๐ซ๐ข๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
Cosmetic Surgery Market
https://www.polarismarketresearch.com/industry-analysis/cosmetic-surgery-market
Hemodialysis and Peritoneal Dialysis Market
https://www.polarismarketresearch.com/industry-analysis/hemodialysis-and-peritoneal-dialysis-market
Hospital Supplies Market
https://www.polarismarketresearch.com/industry-analysis/hospital-supplies-market
India Diagnostic Services Market
https://www.polarismarketresearch.com/industry-analysis/indian-diagnostic-services-market
Intravenous Immunoglobulin Market
https://www.polarismarketresearch.com/industry-analysis/global-intravenous-immunoglobulin-market
๐๐จ๐ง๐ญ๐๐๐ญ:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter
๐๐๐จ๐ฎ๐ญ ๐๐จ๐ฅ๐๐ซ๐ข๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก & ๐๐จ๐ง๐ฌ๐ฎ๐ฅ๐ญ๐ข๐ง๐ , ๐๐ง๐:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-alcoholic Steatohepatitis (NASH) treatment market is expected to reach $90.97 billion by 2034, with a CAGR of 28.0% here
News-ID: 3782940 • Views: โฆ
More Releases from Polaris Market Research & Consulting
Granite Market Projected to Reach USD 6.63 Billion by 2034, Growing at a CAGR of โฆ
Polaris Market Research has released new insights into the Granite market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
In 2024, the market was valued at USD 3.99 billion and is anticipated to grow to USD 6.63 Billion by 2034. Itโฆ
Molecular Diagnostics for Sexually Transmitted Diseases Market to Reach USD 7.85 โฆ
Polaris Market Research announces the release of its latest study on the Molecular Diagnostics For Sexually Transmitted Diseases market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 3.82 billion in 2024 and is expected toโฆ
Higher Alpha Olefins Market Projected to Hit USD 20.01 Billion by 2034, Expandin โฆ
Polaris Market Research announces the release of its latest study on the Higher Alpha Olefins market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 10.39 billion in 2024 and is expected to reach 20.01 billionโฆ
Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2 โฆ
Polaris Market Research announces the release of its latest study on the Direct Oral Anticoagulants (DOACs) Device market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 31.67 billion in 2024 and is expected to reachโฆ
More Releases for NASH
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASHโฆ
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASHโฆ
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 โฆ
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restrainingโฆ
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from theirโฆ
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Donโt Know. Recorded at the legendary RAK Studios, She Donโt Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Donโt Knowโs leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growingโฆ
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nรผrnberg/Germany, 10th September 2010 โ For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies willโฆ
